Answers are grounded in this paper and cite their sources.
Breast cancer remains a serious worldwide health issue with intense biological heterogeneity, disparate clinical patterns, and long-lasting difficulties of metastasis and resistance to therapeutic treatments in spite of extensive advances in diagnostic and therapeutic tools. Limitations of the traditional regimens, such as systemic toxicity, rise of drug resistance, and limited ability of more specific methods of therapy, have forced the search for new, personalized approaches to treatment. Mesenchymal stem cell (MSCs) have emerged as interesting prospects in breast cancer therapy due to their tumor-homing properties, immunomodulatory qualities, and ability to deliver drugs to cells. This review is a critical interrogation of the biology of MSCs, including their origin, phenotypic changes, migration patterns, as well as their immunoregulatory processes in oncological settings. It also unravels the complex interaction between MSCs and the breast cancer microenvironment, which reveals their dualistic roles of tumor-promoters and tumor-suppressors through paracrine signaling, direct cell–cell contact, and MSC-derived exosomes. Especially, the particular focus is given to epithelial–mesenchymal transition, metastatic dissemination, and immune modulation. The review concludes by considering safety issues, such as the possibility of tumor support and malignant transformation, hence supporting the need to carefully regulate and carefully engineer MSC-based interventions. This is a synopsis of all of these to present a complete picture of the therapeutic potential, current challenges, and future translational directions of MSC-based paradigms in the management of breast cancer.
No takes yet. Share an insight, caveat, or question.
Qadir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: